加速生物价值创造中的创新：细胞与基因疗法弹射中心
Accelerating Innovation in the Creation of Biovalue: The Cell and Gene Therapy Catapult.
作者信息
Gardner John, Webster Andrew
机构信息
School of Social Sciences, Monash University, Clayton, Melbourne, Victoria, Australia.
Science and Technology Studies Unit, Department of Sociology, University of York, Heslington, York, United Kingdom.
出版信息
Sci Technol Human Values. 2017 Sep;42(5):925-946. doi: 10.1177/0162243917702720. Epub 2017 Apr 6.
Abstract
The field of regenerative medicine (RM) has considerable therapeutic promise that is proving difficult to realize. As a result, governments have supported the establishment of intermediary agencies to "accelerate" innovation. This article examines in detail one such agency, the United Kingdom's Cell and Gene Therapy Catapult (CGTC). We describe CGTC's role as an accelerator agency and its value narrative, which combines both "health and wealth." Drawing on the notion of sociotechnical imaginaries, we unpack the tensions within this narrative and its instantiation as the CGTC cell therapy infrastructure is built and engages with other agencies, some of which have different priorities and roles to play within the RM field.
摘要
再生医学领域有着可观的治疗前景，但事实证明难以实现。因此，各国政府支持设立中介机构来“加速”创新。本文详细考察了这样一个机构，即英国的细胞与基因治疗弹射中心（CGTC）。我们描述了CGTC作为一个加速机构的角色及其价值理念，该理念融合了“健康与财富”。借助社会技术想象的概念，我们剖析了这一理念内部的紧张关系，以及在CGTC细胞治疗基础设施建设并与其他机构互动过程中这种紧张关系的具体体现，其中一些机构在再生医学领域有着不同的优先事项和作用。
相似文献
1
Accelerating Innovation in the Creation of Biovalue: The Cell and Gene Therapy Catapult.加速生物价值创造中的创新：细胞与基因疗法弹射中心
Sci Technol Human Values. 2017 Sep;42(5):925-946. doi: 10.1177/0162243917702720. Epub 2017 Apr 6.
2
The Cell Therapy Catapult: growing a U.K. cell therapy industry generating health and wealth.细胞治疗弹射器：培育英国细胞治疗产业，创造健康与财富。
Stem Cells Dev. 2013 Dec;22 Suppl 1:35-9. doi: 10.1089/scd.2013.0401.
3
Promissory identities: Sociotechnical representations & innovation in regenerative medicine.承诺身份：再生医学中的社会技术表征与创新
Soc Sci Med. 2017 Feb;174:70-78. doi: 10.1016/j.socscimed.2016.12.018. Epub 2016 Dec 13.
4
Sociotechnical imaginaries of low-carbon waste-energy futures: UK techno-market fixes displacing public accountability.低碳垃圾能源未来的社会技术想象：英国的技术市场解决方案取代了公共问责制。
Soc Stud Sci. 2020 Aug;50(4):609-641. doi: 10.1177/0306312720905084. Epub 2020 Feb 20.
5
Anticipation and modal power: Opening up and closing down the momentum of sociotechnical systems.预期与模态力量：开启与关闭社会技术系统的发展势头
Soc Stud Sci. 2022 Aug 6:3063127221111469. doi: 10.1177/03063127221111469.
6
Bioinformatics and the Politics of Innovation in the Life Sciences: Science and the State in the United Kingdom, China, and India.生物信息学与生命科学创新的政治学：英国、中国和印度的科学与国家
Sci Technol Human Values. 2016 Sep;41(5):793-826. doi: 10.1177/0162243916631022. Epub 2016 Feb 24.
7
The evolution, devolution and distribution of UK Biometric Imaginaries.英国生物识别意象的演变、退化与分布。
Biosocieties. 2022;17(3):506-526. doi: 10.1057/s41292-021-00231-x. Epub 2021 May 5.
8
The everyday lives of energy transitions: Contested sociotechnical imaginaries in the American West.能源转型的日常生活：美国西部备受争议的社会技术想象
Soc Stud Sci. 2016 Jun;46(3):327-350. doi: 10.1177/0306312716644534.
9
Governing through imaginaries: on the place and role of constructions of Japan within UK policy discourse regarding science, technology, and innovation.通过想象进行治理：论日本形象塑造在英国关于科学、技术与创新的政策话语中的地位和作用。
J Law Biosci. 2021 Aug 16;8(2):lsaa007. doi: 10.1093/jlb/lsaa007. eCollection 2021 Jul-Dec.
10
Imaginaries of nuclear energy in the Portuguese parliament: Between promise, risk, and democracy.葡萄牙议会中的核能想象：在承诺、风险与民主之间。
Public Underst Sci. 2017 Apr;26(3):289-306. doi: 10.1177/0963662516662738. Epub 2016 Aug 8.
引用本文的文献
1
Organoids at the forefront of global health: accelerated research and ethical implications in the cases of Zika and COVID-19.类器官处于全球健康前沿：寨卡病毒和新冠疫情案例中的加速研究及伦理影响
Glob Public Health. 2025 Dec;20(1):2496679. doi: 10.1080/17441692.2025.2496679. Epub 2025 May 6.
2
A precision immuno-oncology turn? Hybridizing cancer genomics and immunotherapy through neoantigens-based adoptive cell therapies.精准免疫肿瘤学的转变？通过基于新抗原的过继性细胞疗法融合癌症基因组学与免疫疗法。
Soc Stud Sci. 2025 Aug;55(4):565-590. doi: 10.1177/03063127241303720. Epub 2024 Dec 15.
3
Quantification of bacterial adhesion to tissue in high-throughput kinetics.高通量动力学中细菌对组织黏附的定量分析。
Biol Methods Protoc. 2023 Jul 26;8(1):bpad014. doi: 10.1093/biomethods/bpad014. eCollection 2023.
4
Suitable characteristics in the selection of human allogeneic chondrocytes donors to increase the number of viable cells for cartilage repair.选择人同种异体软骨细胞供体时合适的特征，以增加用于软骨修复的活细胞数量。
Cell Tissue Bank. 2023 Dec;24(4):725-735. doi: 10.1007/s10561-023-10074-4. Epub 2023 Mar 22.
5
Advanced Therapy Medicinal Products' Translation in Europe: A Developers' Perspective.欧洲先进治疗药品的翻译：开发者视角
Front Med (Lausanne). 2022 Feb 3;9:757647. doi: 10.3389/fmed.2022.757647. eCollection 2022.
6
Reimagining Health as a 'Flow on Effect' of Biomedical Innovation: Research Policy as a Site of State Activism.将健康重新想象为生物医学创新的“连带效应”：作为国家行动主义场所的研究政策。
Minerva. 2022;60(2):235-256. doi: 10.1007/s11024-021-09456-3. Epub 2022 Jan 18.
7
Stem cell translational medicine: The Tianjin model revisited.干细胞转化医学：天津模式再探讨。
Stem Cells Transl Med. 2021 Nov;10 Suppl 2(Suppl 2):S4-S9. doi: 10.1002/sctm.20-0494.
8
Cell therapy for cartilage repair.细胞治疗软骨修复。
Emerg Top Life Sci. 2021 Oct 29;5(4):575-589. doi: 10.1042/ETLS20210015.
9
Accomplishing an adaptive clinical trial for cancer: Valuation practices and care work across the laboratory and the clinic.完成癌症适应性临床试验：实验室和临床之间的评估实践和护理工作。
Soc Sci Med. 2020 May;252:112949. doi: 10.1016/j.socscimed.2020.112949. Epub 2020 Mar 24.
本文引用的文献
1
Rethinking in the Bio-economy: Finance, Assetization, and the Management of Value.生物经济中的反思：金融、资产化与价值管理
Sci Technol Human Values. 2017 May;42(3):460-490. doi: 10.1177/0162243916661633. Epub 2016 Aug 10.
2
Promissory identities: Sociotechnical representations & innovation in regenerative medicine.承诺身份：再生医学中的社会技术表征与创新
Soc Sci Med. 2017 Feb;174:70-78. doi: 10.1016/j.socscimed.2016.12.018. Epub 2016 Dec 13.
3
Betting on hepatitis C: how financial speculation in drug development influences access to medicines.押注丙型肝炎：药物研发中的金融投机如何影响药物可及性。
BMJ. 2016 Jul 27;354:i3718. doi: 10.1136/bmj.i3718.
4
Opening the gateways to market and adoption of regenerative medicine? The UK case in context.打开再生医学的市场之门并推动其应用？英国的相关情况。
Regen Med. 2016 Apr;11(3):321-30. doi: 10.2217/rme-2015-0046.
5
The social management of biomedical novelty: Facilitating translation in regenerative medicine.生物医学新事物的社会管理：促进再生医学中的转化
Soc Sci Med. 2016 May;156:90-7. doi: 10.1016/j.socscimed.2016.03.025. Epub 2016 Mar 18.
6
Biobanking human embryonic stem cell lines: policy, ethics and efficiency.人类胚胎干细胞系生物样本库：政策、伦理与效率
Monash Bioeth Rev. 2015 Dec;33(4):265-76. doi: 10.1007/s40592-015-0050-y.
7
Are there specific translational challenges in regenerative medicine? Lessons from other fields.再生医学中是否存在特定的转化挑战？来自其他领域的经验教训。
Regen Med. 2015;10(7):885-95. doi: 10.2217/rme.15.50. Epub 2015 Nov 6.
8
Guidelines for the use of cell lines in biomedical research.生物医学研究中细胞系使用指南。
Br J Cancer. 2014 Sep 9;111(6):1021-46. doi: 10.1038/bjc.2014.166. Epub 2014 Aug 12.
9
The Cell Therapy Catapult: growing a U.K. cell therapy industry generating health and wealth.细胞治疗弹射器：培育英国细胞治疗产业，创造健康与财富。
Stem Cells Dev. 2013 Dec;22 Suppl 1:35-9. doi: 10.1089/scd.2013.0401.
10
Closing the regulatory regress: GMP accreditation in stem cell laboratories.终结监管倒退：干细胞实验室的GMP认证
Sociol Health Illn. 2013 Mar;35(3):345-60. doi: 10.1111/j.1467-9566.2012.01482.x. Epub 2012 Aug 7.
Zotero 插件